Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field
Source: SeekingAlpha
2026-04-27 18:28:24 ET
Investment Overview - Explaining Perspective's Stock Surge In 2026
Perspective Therapeutics ( CATX ) is a radiopharmaceuticals specialist that went public in February 2023, via the merger of Nasdaq listed Isoray Inc., and privately held Viewpoint Molecular Targeting....
Read the full article on Seeking Alpha
For further details see:
Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field
Isoray. (DE)
NASDAQ: CATX
CATX Trading
-4.33% G/L:
$3.095 Last:
869,961 Volume:
$3.25 Open:
CATX Latest News
June 03, 2026 06:30:00 am
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-?-NET in the Meningioma Cohort of a Phase 1/2a Study
May 21, 2026 05:51:13 pm
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
May 18, 2026 06:30:00 am
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
May 11, 2026 04:07:00 pm
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
CATX Stock Data
$352,362,073
59,849,516
0.09%
33
N/A
Medical Equipment & Supplies
Healthcare
US
Seattle
